Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 25;5:35. doi: 10.1038/s41523-019-0131-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — ROR1^P(841)A fails to associate with cortactin, induce phosphorylation of cortactin, or enhance migration of MCF7 cells. a Schematic depicts the structure of ROR1 protein with different domains. b ΔPRD represents the truncated form of ROR1 without its proline-rich region (PRD). c Amino acid sequences of the PRD of ROR1. Asterisks indicate the proline (P) residues that were replaced with alanine (A). d Immunoblots of anti-ROR1 i.p. by using lysates of MCF7 (Ctrl), MCF7–WT ROR1, or MCF7 cells transfected with ROR1–ΔPRD, as indicated on the top, and probed with antibodies specific for ROR1 or cortactin, as indicated on the left. An immunoblot of the WCL probed with anti-cortactin mAb is in the bottom panel. e Immunoblots of anti-ROR1 i.p. by using lysates of MCF7-Ctrl, MCF7–ΔPRD, MCF7–WT ROR1, or MCF7 transfected with each of the various mutated forms of ROR1, as indicated on the top, and probed with antibodies specific for ROR1, cortactin, or ARHGEF1, as indicated on the left. An immunoblot of the WCL probed with anti-cortactin is in the bottom panel. f Immunoblots of lysates prepared from serum-starved MCF7 (Ctrl), MCF7–ΔPRD, MCF7–WT ROR1, or MCF7 cells transfected with each of the various mutated forms of ROR1, as indicated on top, which subsequently were treated without (−) or with (+) Wnt5a (100 ng/ml), as indicated on the top; the membranes were probed with antibodies specific for ROR1, Cortactin, or pCortactin, as indicated on the left. g Immunoblot of activated RhoA (RhoA–GTP, top panel) or total RhoA (RhoA total, bottom panel) found in lysates of MCF7 (Ctrl), MCF7–ΔPRD, MCF7–WT ROR1, or MCF7 expressing any one of the various mutant forms of ROR1, as indicated on top of each lane in Fig. 1f. h Columns indicate the mean number of migrated cells at 10 h of MCF7 (Ctrl), MCF7–ΔPRD, MCF7 expressing any one of the various mutant forms of ROR1, or MCF7–WT ROR1, as indicated below, which were serum-starved and then examined for migration without (−) or with (+) Wnt5a (200 ng/ml), as indicated at the bottom. Data are shown from three independent experiments (P < 0.05; P < 0.01, as calculated by one-way ANOVA with Bonferroni’s multiple-comparison test).